These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6119275)

  • 1. Increased suppressor cell activity in inflammatory bowel disease.
    Holdstock G; Chastenay BF; Krawitt EL
    Gut; 1981 Dec; 22(12):1025-30. PubMed ID: 6119275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of leucocyte motility by drugs used in ulcerative colitis.
    Rhodes JM; Bartholomew TC; Jewell DP
    Gut; 1981 Aug; 22(8):642-7. PubMed ID: 6116649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional suppressor T cell activity in Crohn's disease and the effects of sulphasalazine.
    Holdstock G; Chastenay BF; Krawitt EL
    Clin Exp Immunol; 1982 Jun; 48(3):619-24. PubMed ID: 6126286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulphasalazine and derivatives, natural killer activity and ulcerative colitis.
    Gibson PR; Jewell DP
    Clin Sci (Lond); 1985 Aug; 69(2):177-84. PubMed ID: 2866061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease.
    Doering J; Begue B; Lentze MJ; Rieux-Laucat F; Goulet O; Schmitz J; Cerf-Bensussan N; Ruemmele FM
    Gut; 2004 Nov; 53(11):1632-8. PubMed ID: 15479684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of prostaglandin synthetase in human rectal mucosa.
    Hawkey CJ; Lo Casto M
    Gut; 1983 Mar; 24(3):213-7. PubMed ID: 6131017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes--clues to its clinical action?
    Sheldon P; Webb C; Grindulis KA
    Br J Rheumatol; 1988 Oct; 27(5):344-9. PubMed ID: 2902897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity.
    Aparicio-Pagés MN; Verspaget HW; Hafkenscheid JC; Crama-Bohbouth GE; Peña AS; Weterman IT; Lamers HW
    Gut; 1990 Sep; 31(9):1030-2. PubMed ID: 1976576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?
    Bird HA
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():16-9. PubMed ID: 8535642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of aminosalicylic acid derivatives on nitric oxide in a cell-free system.
    Reynolds PD; Middleton SJ; Shorthouse M; Hunter JO
    Aliment Pharmacol Ther; 1995 Oct; 9(5):491-5. PubMed ID: 8580268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sulphasalazine and its metabolites on prostaglandin synthesis, inactivation and actions on smooth muscle.
    Hoult JR; Moore PK
    Br J Pharmacol; 1980 Apr; 68(4):719-30. PubMed ID: 6103724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid.
    Greenfield SM; Punchard NA; Thompson RP
    Gut; 1991 Oct; 32(10):1156-9. PubMed ID: 1683330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine.
    Allgayer H; Eisenburg J; Paumgartner G
    Eur J Clin Pharmacol; 1984; 26(4):449-51. PubMed ID: 6428914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ulcerative colitis: effect of sulphasalazine, its metabolites and indomethacin on the ability of human colonic mucosa to metabolize prostaglandins in vitro.
    Hillier K; Mason PJ; Pacheco S; Smith CL
    Br J Pharmacol; 1982 May; 76(1):157-61. PubMed ID: 6123357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of antibody secretion by 5-aminosalicylic acid.
    MacDermott RP; Schloemann SR; Bertovich MJ; Nash GS; Peters M; Stenson WF
    Gastroenterology; 1989 Feb; 96(2 Pt 1):442-8. PubMed ID: 2562949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects?
    Aruoma OI; Wasil M; Halliwell B; Hoey BM; Butler J
    Biochem Pharmacol; 1987 Nov; 36(21):3739-42. PubMed ID: 2890355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species.
    Miyachi Y; Yoshioka A; Imamura S; Niwa Y
    Gut; 1987 Feb; 28(2):190-5. PubMed ID: 2881849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen.
    Sheldon P; Pell P
    Br J Clin Pharmacol; 1993 Mar; 35(3):261-4. PubMed ID: 8097101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of sulphasalazine on the in vitro activation of human peripheral blood mononuclear cells by phytohemagglutinin P.
    Pacheco S; Jones DB; Hillier K
    Braz J Med Biol Res; 1989; 22(4):513-6. PubMed ID: 2574059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.